Study design: A cross-sectional multi-center study using an on-line survey addressing utilization, knowledge, and perceptions of medicinal cannabis (MC) by people with spinal cord injury (SCI).
Objective: To characterize differences between current (CU), past (PU), and never users (NU) of MC with SCI; to determine why people with SCI use MC; to examine reports of MCs' efficacy and tolerability by individuals with SCI.
Setting: Three academic medical centers in the United States.
Methods: Comparison of demographic and attitudinal differences between CU, PU, and NU and differences in the groups' reports of pain, health, and quality of life (QOL). Evaluation of utilization patterns and perceived efficacy of MC among CU and PU and reports of side effects of MC versus prescription medications. Data were analyzed using either Chi Square, distribution-free exact statistics, or t-tests for continuous data.
Results: Among a nationwide sample (n = 353) of individuals with SCI, NU were less likely than CU and PU to believe that cannabis ought to be legalized and more likely to endorse risks of use. Current users and PU reported greater pain interference in daily life than did NU, but there were no between group differences in QOL or physical or emotional health. Current users and PU took MC to address pain (65.30%), spasms (63.30%), sleeplessness (32.70%), and anxiety (24.00%), and 63.30% reported it offered "great relief" from symptoms. Participants reported that MC is more effective and carries fewer side effects than prescription medications.
Conclusions: Medicinal cannabis is an effective and well-tolerated treatment for a number of SCI-related symptoms.
Keywords: Quality of life; Spinal cord diseases.
© The Author(s), under exclusive licence to International Spinal Cord Society 2019.
Conflict of interest statement
Conflict of interestThe authors declare that they have no conflict of interest.
Attitudes toward and knowledge of medical cannabis among individuals with spinal cord injury.Spinal Cord Ser Cases. 2019 Jan 18;5:6. doi: 10.1038/s41394-019-0151-6. eCollection 2019. Spinal Cord Ser Cases. 2019. PMID: 30675390 Free PMC article.
Self-Efficacy and Pressure Ulcer Prevention After Spinal Cord Injury-Results From a Nationwide Community Survey in Switzerland (SwiSCI).PM R. 2018 Jun;10(6):573-586. doi: 10.1016/j.pmrj.2017.11.017. Epub 2017 Dec 7. PM R. 2018. PMID: 29225161 Clinical Trial.
Hospital based care at home; study protocol for a mixed epidemiological and randomized controlled trial.Trials. 2019 Jan 24;20(1):77. doi: 10.1186/s13063-019-3185-y. Trials. 2019. PMID: 30678710 Free PMC article. Clinical Trial.
The use of cannabis in response to the opioid crisis: A review of the literature.Nurs Outlook. 2018 Jan-Feb;66(1):56-65. doi: 10.1016/j.outlook.2017.08.012. Epub 2017 Sep 21. Nurs Outlook. 2018. PMID: 28993073 Review.
Cannabis-based medicines for chronic neuropathic pain in adults.Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2. Cochrane Database Syst Rev. 2018. PMID: 29513392 Free PMC article. Review.